Niraparib CAS NO.1038915-60-4

Niraparib is a highly selective, potent oral PARP inhibitor used primarily in oncology to treat various forms of cancer, particularly ovarian and prostate cancers with BRCA mutations. It is designed as a targeted therapy to exploit DNA repair deficiencies in tumor cells, offering high efficacy with manageable side effects for patients requiring maintenance treatment after chemotherapy or as a monotherapy in recurrent settings. The product is available in high purity suitable for both pharmaceutical research and clinical development purposes.

business@huanqiukeji9.com

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Niraparib
CAS NO.	1038915-60-4
Appearance	White to off-white powder
Molecular Formula	C₁₉H₂₀N₄O
Molecular Weight	320.39 g/mol
Purity (RP-HPLC)	≥98%
Solubility	Soluble in DMSO and ethanol; slightly soluble in water
Endotoxin	< 1.0 EU/mg
Biological Activity	Potent and selective PARP inhibitor (PARP1, PARP2); induces synthetic lethality in BRCA-mutated tumor cells
Storage Conditions	Store at -20°C, protected from light and moisture
Stock Location	USA, EU, CN (Based on actual stock)
MOQ	1 mg

1.Mechanism of Action

Niraparib exerts its therapeutic effect by binding reversibly to the catalytic domain of poly (ADP-ribose) polymerase (PARP), thereby inhibiting PARP-mediated DNA repair processes. In tumor cells with homologous recombination deficiencies (HRD), including those with BRCA1/2 mutations, this inhibition leads to the accumulation of DNA double-strand breaks and subsequent cell death through synthetic lethality. Its ability to maintain target engagement even in the absence of constant binding makes it effective across various dosing schedules and patient populations.

upload/attachment/image/202605/25/177967385516a36fc84abc69ca1cb9aa0f0468b326_local.png

upload/attachment/image/202605/25/1779673861f864473ff4b449818cc60fd3017850d4_local.png

2.Product Indications

Niraparib is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, as well as for the treatment of patients with recurrent ovarian cancer regardless of BRCA mutation status. It is also approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair gene mutations. This makes it a versatile option for oncologists managing BRCA-mutated and HRD-positive malignancies.

upload/attachment/image/202605/25/1779673898dd887ee256e1d71dbfc37a57e4875047_local.png

3.Clinical Efficacy of Product

Clinically, Niraparib has demonstrated significant progression-free survival (PFS) benefits in multiple Phase III trials, notably in the NOVA and PRIMA studies, where it showed superior efficacy compared to placebo in both BRCA-mutated and non-mutated patient cohorts. The drug has been shown to provide durable responses and delay disease progression in heavily pretreated patients, with a favorable safety profile that supports long-term administration. Its oral formulation enhances patient compliance and quality of life, making it a preferred choice in ongoing cancer management strategies.

upload/attachment/image/202605/25/17796739166ac23c46d3667ba681251ff810c6236d_local.png

4.Certificate

GlobalTech Co., Ltd. is committed to providing high-purity biotechnological peptide products, adhering strictly to quality standards and obtaining internationally recognized certifications.

Our production partners all employ GMP-compliant production systems and possess standardized quality control processes covering raw material procurement, synthesis, purification, testing, packaging, and storage. Each batch of product comes with complete documentation, including a Certificate of Analysis (COA), HPLC purity report, mass spectrometry (MS) chromatograms, and third-party testing reports available upon request.

We prioritize:

1.A rigorous quality management system

2.Batch traceability and stability data

3.Professional laboratory testing and validation

4.Compliance with international trade standards

Our commitment to quality, transparency, and regulatory compliance ensures the provision of reliable, stable, and research-grade peptide products to our global partners.

poricoic acid A CAS NO.137551-38-3

5.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.

Professional and Secure Packaging

Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.

We can also customize packaging according to customer needs.

Shipping Methods

Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.

poricoic acid A CAS NO.137551-38-3

Global Technology Co., Ltd. is a modern and advanced enterprise specializing in the production and export of active pharmaceutical ingredients (APIs), peptides, and plant extracts. The company invests in and collaborates closely with domestic manufacturers holding GMP, DMF, and FDA certifications, as well as laboratories at renowned universities, to meet diverse customer needs ranging from gram-level to ton-level. This enables Dejurui Pharmaceutical to provide customers with more flexible and convenient access to cost-effective, high-quality products and superior services.

We focus on the research and development and supply of high-quality chemical products, strictly adhering to international standards and quality systems. Our products are stable in performance and reliable in purity, widely used in industrial manufacturing, scientific research, and the fine chemical industry. We provide solid support at every stage with a professional and responsible attitude.

HotTags:Niraparib, #PARPinhibitor, #CancerTreatment, #OncologyDrug, #BRCAmutation, #TargetedTherapy, #PharmaceuticalGrade, #ClinicalResearch, #CancerResearch, #DNARepairInhibitor, #EpithelialOvarianCancer, #ProstateCancer, #HighPurityChemical, #SyntheticLethality, #NOVAstudy